We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.
- Authors
Funakoshi, Yohei; Yakushijin, Kimikazu; Ohji, Goh; Hojo, Wataru; Sakai, Hironori; Watanabe, Marika; Kitao, Akihito; Miyata, Yoshiharu; Saito, Yasuyuki; Kawamoto, Shinichiro; Yamamoto, Katsuya; Ito, Mitsuhiro; Koyama, Taiji; Imamura, Yoshinori; Kiyota, Naomi; Matsuoka, Hiroshi; Mori, Yasuko; Minami, Hironobu
- Abstract
Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
- Subjects
VACCINATION; CANCER cells; SARS-CoV-2; IMMUNOGLOBULINS; ANTIBODY titer
- Publication
Vaccines, 2022, Vol 10, Issue 6, pN.PAG
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10060965